Kenvue Inc. (NYSE:KVUE) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 38.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 406,467 shares of the company’s stock after purchasing an additional 113,157 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Kenvue were worth $8,677,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Grove Bank & Trust increased its holdings in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the period. Riverview Trust Co purchased a new stake in shares of Kenvue in the 3rd quarter valued at $30,000. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the fourth quarter worth $29,000. Ashton Thomas Securities LLC purchased a new stake in Kenvue in the third quarter valued at $35,000. Finally, Fortitude Family Office LLC grew its position in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the topic of a number of recent research reports. Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. UBS Group dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday. Bank of America boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group decreased their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Trading Up 2.2 %

Shares of KVUE opened at $20.23 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a market cap of $38.79 billion, a PE ratio of 36.78, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. The firm’s fifty day moving average is $21.61 and its two-hundred day moving average is $21.93. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.